Repligen Co. (NASDAQ:RGEN) Stock Position Raised by Blue Trust Inc.

Blue Trust Inc. raised its position in shares of Repligen Co. (NASDAQ:RGEN) by 113.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239 shares of the biotechnology company’s stock after purchasing an additional 127 shares during the period. Blue Trust Inc.’s holdings in Repligen were worth $36,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Repligen by 30.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Swedbank AB acquired a new position in shares of Repligen during the 1st quarter valued at about $5,518,000. Banque Pictet & Cie SA increased its holdings in shares of Repligen by 74.6% during the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after acquiring an additional 14,746 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after acquiring an additional 21,719 shares during the last quarter. Finally, Diversified Trust Co increased its holdings in shares of Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after acquiring an additional 106 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $138.61 on Friday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The firm has a market capitalization of $7.76 billion, a PE ratio of -3,355.91, a PEG ratio of 3.92 and a beta of 0.95. The business’s 50 day moving average is $142.20 and its 200-day moving average is $146.15. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same quarter last year, the firm earned $0.53 EPS. Repligen’s revenue for the quarter was down 3.2% compared to the same quarter last year. Sell-side analysts predict that Repligen Co. will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on RGEN. Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. UBS Group lowered their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Wells Fargo & Company began coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.